Your browser doesn't support javascript.
loading
Modeling SARS-CoV-2 and Influenza Infections and Antiviral Treatments in Human Lung Epithelial Tissue Equivalents
Hoda Zarkoob; Anna Allue-Guardia; Yu-Chi Chen; Olive Jung; Andreu G. Vilanova; Minjae Song; Jun-Gyu Park; Fatai Oladunni; Jesse Miller; Yen-Ting Tung; Ivan Kosik; David Schultz; jonathan yewdell; Jordi B Torrelles; Luis Martinez-Sobrido; Sara Cherry; Marc Ferrer; Emily M. Lee.
Afiliación
  • Hoda Zarkoob; National Center for Advancing Translational Sciences
  • Anna Allue-Guardia; Texas Biomedical Research Institute
  • Yu-Chi Chen; National Center for Advancing Translational Sciences
  • Olive Jung; National Center for Advancing Translational Sciences
  • Andreu G. Vilanova; Texas Biomedical Research Institute
  • Minjae Song; National Center for Advancing Translational Sciences
  • Jun-Gyu Park; Texas Biomedical Research Institute
  • Fatai Oladunni; Texas Biomedical Research Institute
  • Jesse Miller; University of Pennsylvania
  • Yen-Ting Tung; National Center for Advancing Translational Sciences
  • Ivan Kosik; National Institute of Allergies and Infectious Diseases
  • David Schultz; University of Pennsylvania
  • jonathan yewdell; NIAID
  • Jordi B Torrelles; Texas Biomedical Research Institute
  • Luis Martinez-Sobrido; Texas Biomedical Research Institute
  • Sara Cherry; University of Pennsylvania
  • Marc Ferrer; National Center for Advancing Translational Sciences
  • Emily M. Lee; National Center for Advancing Translational Sciences
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-443693
ABSTRACT
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the third coronavirus in less than 20 years to spillover from an animal reservoir and cause severe disease in humans. High impact respiratory viruses such as pathogenic beta-coronaviruses and influenza viruses, as well as other emerging respiratory viruses, pose an ongoing global health threat to humans. There is a critical need for physiologically relevant, robust and ready to use, in vitro cellular assay platforms to rapidly model the infectivity of emerging respiratory viruses and discover and develop new antiviral treatments. Here, we validate in vitro human alveolar and tracheobronchial tissue equivalents and assess their usefulness as in vitro assay platforms in the context of live SARS-CoV-2 and influenza A virus infections. We establish the cellular complexity of two distinct tracheobronchial and alveolar epithelial air liquid interface (ALI) tissue models, describe SARS-CoV-2 and influenza virus infectivity rates and patterns in these ALI tissues, the viral-induced cytokine production as it relates to tissue-specific disease, and demonstrate the pharmacologically validity of these lung epithelium models as antiviral drug screening assay platforms.
Licencia
cc0
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Prognostic_studies Idioma: En Año: 2021 Tipo del documento: Preprint